Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cronos GroupSTU:7CI -0.33%85 3-Year RORE % is 1,750.00 as of Mar. 2026. GuruFocus rates STU:7CI with a GF Score™ of 85/100 and a GF Value™ of €3.11 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 940 Drug Manufacturers companies, Cronos Group ranks better than 99.15% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Cronos Group's 3-Year RORE % for the quarter that ended in Mar. 2026 was 1,750.00%.
The industry rank for Cronos Group's 3-Year RORE % or its related term are showing as below:
STU:7CI's 3-Year RORE % is ranked better than 99.15% of 940
companies
in the Drug Manufacturers industry
Industry Median: 3.075
vs STU:7CI: 1750.00
Cronos Group (STU:7CI) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Cronos Group 3-Year RORE % Related Terms
Cronos Group 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Cronos Group's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Cronos Group's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Cronos Group (STU:7CI) has a 3-Year RORE % of 1,750.00 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Cronos Group and its competitors. According to the industry distribution chart, Cronos Group ranks #8 out of 940 companies in the Drug Manufacturers industry, placing it in the top 0.90000000000001%.
Is Cronos Group's 3-Year RORE % too high?
Cronos Group's current 3-Year RORE % is 1,750.00. The Drug Manufacturers industry median 3-Year RORE % is 3.08. Cronos Group's value of 1,750.00 is 56810.6% above this industry median. Based on the distribution chart, Cronos Group ranks #8 out of 940 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cronos Group has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's 3-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #8 out of 940 companies for 3-Year RORE %. This places Cronos Group in the top 1% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 3.08. Cronos Group's value of 1,750.00 is 56810.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.08, based on 940 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current 3-Year RORE % of 1,750.00 is 56810.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current 3-Year RORE % is 1,750.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (STU:7CI) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.11, compared to a current price of €2.40 — trading 22.9% below its estimated fair value. The current 3-Year RORE % is 1,750.00 and 56810.6% above the Drug Manufacturers industry median of 3.08. Cronos Group's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Cronos Group (STU:7CI), the current 3-Year RORE % is 1,750.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (STU:7CI) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of €2.40 is trading 22.9% below its estimated GF Value™ of €3.11.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for STU:7CI:
3-Year RORE %: 1,750.00
GF Value™: €3.11 vs. price of €2.40 (22.9% below fair value)
Industry Position: 56810.6% above the Drug Manufacturers median (#8 of 940)
No single metric tells the full story. See the STU:7CI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
85GF Score
Get the complete analysis for STU:7CI
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7CI has been successfully added to your 
